C5813
Complement factor H from human plasma
1 mg/mL in PBS, pH 7.2, ≥90% (SDS-PAGE)
Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)
About This Item
Empfohlene Produkte
Anwendung
Complement factor H (CFH) is a plasma regulator of the complement protein C3b in the alternative pathway of the complement system. Research has shown that binding of CFH is important for pathogenesis of group A streptococcus (GAS), and inhibition of this binding may be an effective management of GAS infections.
Biochem./physiol. Wirkung
Complement factor H plays an essential role in the homeostasis of the complement system and in preventing collateral damage to bystander cells and tissues by complement activation.
C3b-binding protein which regulates the formation and function of complement C3 and C5 convertases.
Sonstige Hinweise
View more information on the complement pathway at www.sigma-aldrich.com/enzymeexplorer
Haftungsausschluss
RESEARCH USE ONLY. This product is regulated in France when intended to be used for scientific purposes, including for import and export activities (Article L 1211-1 paragraph 2 of the Public Health Code). The purchaser (i.e. enduser) is required to obtain an import authorization from the France Ministry of Research referred in the Article L1245-5-1 II. of Public Health Code. By ordering this product, you are confirming that you have obtained the proper import authorization.
Lagerklassenschlüssel
10 - Combustible liquids
Flammpunkt (°F)
Not applicable
Flammpunkt (°C)
Not applicable
Analysenzertifikate (COA)
Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.
Besitzen Sie dieses Produkt bereits?
In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.
D T Fearon et al.
Proceedings of the National Academy of Sciences of the United States of America, 74(4), 1683-1687 (1977-04-01)
The surface of zymosan (Zy), by affording a protected microenvironment for C3b and the amplification convertase stabilized by properdin, P,C3b,Bb, shifts the alternative complement pathway from slow fluid phase turnover to the amplification phase of its expression. This mode of
Arife Uslu-Gökceoğlu et al.
The Turkish journal of pediatrics, 55(1), 86-89 (2013-05-23)
Atypical hemolytic uremic syndrome (aHUS) is a disease caused by pathologies in the alternative complement system. The prevalence of aHUS is 10% of all aHUS cases. The subgroup of aHUS designated as DEAP (DEficiency of CFHR Proteins and CFH Autoantibody
A Massart et al.
Acta clinica Belgica, 68(1), 9-14 (2013-05-01)
Atypical haemolytic uraemic syndrome (aHUS) results from uncontrolled complement system activation. Complement factor H gene mutations are common causes of aHUS. Plasmatherapy, including plasma infusions and/or plasma exchanges, has been tried in this setting with various successes. At present, we
Christoph Q Schmidt et al.
Journal of immunology (Baltimore, Md. : 1950), 190(11), 5712-5721 (2013-04-26)
Inadequate control of the complement system is the underlying or aggravating factor in many human diseases. Whereas treatment options that specifically target the alternative pathway (AP) of complement activation are considered highly desirable, no such option is available in the
Complement Factor H-ligand interactions: Self-association, multivalency and dissociation constants.
Perkins SJ., et al.
Immunobiol. (2011)
Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..
Setzen Sie sich mit dem technischen Dienst in Verbindung.